Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Sareum Holdings plc
Pharmaceutical Preparation ManufacturingUnited Kingdom
Last verified 6 months agosareum.com
Sareum Holdings plc, a prominent biopharmaceutical company based in Great Britain, focuses on the discovery and development of innovative cancer therapies and autoimmune disease treatments. Founded in 2006, Sareum has made significant strides in the pharmaceutical industry, particularly in the fields of kinase inhibitors and small molecule drug development.
With its headquarters in the UK, Sareum operates primarily within the biotechnology sector, leveraging its proprietary drug discovery platform to create unique therapeutic candidates. The company has achieved notable milestones, including partnerships with leading pharmaceutical firms, which underscore its strong market position. Sareum's commitment to advancing healthcare through cutting-edge research and development sets it apart in a competitive landscape, making it a key player in the fight against serious diseases.
21
DitchCarbon score
-21 vs industry average
Sareum Holdings plc’s score of 21 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sareum Holdings plc?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Medium
Pharmaceutical Preparation Manufacturing has typical carbon intensity
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Sareum Holdings plc yet.
Sareum Holdings plc's reported carbon emissions
Sareum Holdings plc, headquartered in Great Britain, currently does not have any reported carbon emissions data for the latest year. As such, there are no specific figures available for Scope 1, Scope 2, or Scope 3 emissions. Additionally, the company has not established any documented reduction targets or climate pledges at this time.
In the absence of emissions data and reduction initiatives, it is important to note that many organisations in the biotechnology sector are increasingly focusing on sustainability and climate commitments. This trend often includes setting science-based targets and participating in initiatives aimed at reducing carbon footprints. However, without specific commitments or data from Sareum Holdings plc, further details cannot be provided.
Assessing Sareum Holdings plc as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Sareum Holdings plc and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Sareum Holdings plc’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Sareum Holdings plc yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Sareum Holdings plc6 months ago
21
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more